Allogenic stem cell transplant can cure high-risk CLL


Although most cases of small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) are considered indolent and can be effectively treated with chemotherapy, some patients do not respond to traditional treatments. These patients are considered high-risk, and in them the disease can be fatal within just a few years.

To address this group of patients, the German CLL Study Group (GCLLSG) undertook a multicenter (16) clinical phase II study that included 90 patients with high-risk SLL/CLL. In this so-called CLL3X trial, all patients received pre-transplant chemotherapy followed by an allogenic stem cell transplant. Findings indicated that, at a median follow-up of four years, approximately half of the cohort was disease-free, leading the study's authors to conclude that this treatment has the potential to cure some patients in the high-risk group.


Allogenic stem cell transplant. In this treatment, the patient receives stem cells from a matching donor.


Online in the journal Blood.

By Ross Bonander

LymphomaInfo Social